2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 523

Association Between The Presence Of Amyloidosis In Patients With Ankylosing Spondylitis and Polymorphisms In Type 1/Type 2 Serum Amyloid A Protein Genes, Mediterranean Fever Genes
Abstract Number: 882

Association Of a Neutrophil Gene Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes With Both Future Systemic Lupus Erythematosus Disease Activity and Poor Longterm Outcomes
Abstract Number: 1894

Association Of Alleles and Amino Acids Of The Major Histocompatibility Complex Class I Chain-Related Gene A With Psoriatic Disease
Abstract Number: 19

Association Of Antiphospholipid Antibodied Detected In The Aphl ELISA With Clinical Manifestations Of The Antiphospholipid Syndrome In Two Lupus Cohorts
Abstract Number: 102

Association Of Area-Level Socioeconomic Status With Pain and Function At Presentation For Total Knee Arthroplasty
Abstract Number: 2855

Association Of Back Pain With Functional Limitations In Patients With Knee and Hip Osteoarthritis
Abstract Number: 170

Association Of BMI, 8 SNPs Reported To Be Related To Gout Phenotype and Their Interaction In Gout Incidence In Framingham Heart Study
Abstract Number: 1009

Association Of Depressive Symptomatology and Life and Job Satisfaction In Patients With Rheumatoid Arthritis
Abstract Number: 1010

Association Of Depressive Symptomatology and Life and Job Satisfaction In Patients With Systemic Lupus Erythematosus
Abstract Number: 167

Association Of Functional Polymorphisms In IRF2 With Systemic Lupus Erythematosus In a Japanese Population
Abstract Number: 2409

Association Of High Serum Interleukin-23 Levels With Porphyromonas Gingivalis Antibodies In Patients With Early Rheumatoid Arthritis
Abstract Number: 1737

Association Of HLA-DRB1 Alleles With Clinical Responses To The Anti-Interleukin−17A Monoclonal Antibody Secukinumab In a Cohort Of Patients With Active Rheumatoid Arthritis: An Exploratory Phase 2 Biomarker Study
Abstract Number: 2333

Association Of Mean Changes In Laboratory Safety Parameters With C-Reactive Protein At Baseline and Week 12 In Rheumatoid Arthritis Patients Treated With Tofacitinib
Abstract Number: 2527

Association Of Nail Dystrophy With Capillaroscopic Abnormalities, Anti-Endothelial Cell Antibody, Endothelin-1, Activity and Chronicity In Systemic Lupus Erythematosus
Abstract Number: 575

Association Of Psoriasis and Psoriatic Arthritis With Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].